BioSpace News Archive

Aura Biosciences, Inc. (“Aura”), a clinical-stage oncology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced the pricing of its initial public offering of 5,400,000 shares of common stock at a public offering price of $14.00 per share.

Entrada Therapeutics, Inc., a biotechnology company aiming to transform the lives of patients by establishing Endosomal Escape Vehicle therapeutics as a new class of medicines and aiming to become the world’s foremost intracellular therapeutics company, announced the pricing of its upsized initial public offering of 9,075,000 shares of common stock, at a price to the public of $20.00 per share.

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2021 results on Thursday, November 11, 2021, after the market close.

Spirovant Sciences, a gene therapy company developing treatments and cures for inherited respiratory diseases including cystic fibrosis (CF), today announced that it will be delivering oral and poster presentations highlighting pre-clinical data for its compound, SP-101, at the 2021 North American Cystic Fibrosis Conference (NACFC 2021).

Pendulum Therapeutics, a trailblazer in microbiome science and a pioneer in DNA sequencing, is leading healthcare professional education on the microbiome and its relationship to metabolic disease, including type 2 diabetes.

Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today it will release its financial results for the third quarter of 2021 on Thursday, November 11, 2021.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended September 30, 2021 on Thursday, November 4, 2021, after the close of the U.S. financial markets.

Miromatrix Medical Inc., a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, announced that the Company will report financial results for the third quarter 2021 after market close on Monday, November 15, 2021.

Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today announced recent corporate updates and financial results for the third quarter ended September 30, 2021.

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing STS101 nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, announced that John Kollins, its President and Chief Executive Officer, is scheduled to present in the month of November at the following conferences and invites investors to participate via webcast and in virtual one-on-one meetings.